Research
Hormonal
Post-bariatric surgery weight regain (affecting 15-20% of patients) can be managed with endoscopic interventions or OMM, but optimal dosing and scheduling for these combination therapies remain undefined.
If you regain weight after surgery (affecting 15-20% of patients), you are not out of options. Endoscopic procedures or adding back medications like GLP-1s can help, but doctors currently lack clear guidelines on the best doses and schedules for this specific scenario.
ModerateQualifiesMEDIUM confidence
Whilst some degree of recurrent weight gain is to be expected after any MBS procedure, around 15–20% of people will experience weight recurrence that impacts their health and necessitates reintervention... it was noted that there is currently limited evidence regarding the best dosing, best schedule, and potential adverse effects of adding OMM in this situation
Why this rating
Based on limited RCT data and real-world data, with explicit acknowledgment of evidence gaps.
Source
The Future of Obesity Care: Exploring Synergies Between Metabolic Bariatric Surgery, Interventional Endoscopy and Pharmacotherapy
Wendy A. Brown et al. · Obesity Surgery · 2026
DOI 10.1007/s11695-026-08692-4
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- New generation obesity medications (GLP-1/GIP agonists) achieve mean weight loss of 15–25% over 68–72 weeks, narrowing the efficacy gap between medical and surgical management of obesity.Good
- Combining obesity management medications (OMM) with metabolic bariatric surgery (MBS) or endoscopic procedures is an inevitable and necessary component of future personalized obesity care, though optimal protocols are currently undefined.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →